Inimmune
Founded 2016 · 36 employees on LinkedIn · 1 known investors
Inimmune is a clinical-stage biotech company that discovers and develops immunotherapies based on innate immune modulation, including Toll-like receptor agonists, to treat inflammatory conditions such as allergy, cancer, and autoimmune disease. Its lead program, INI-2004, is an intranasal TLR4 agonist in Phase 2 trials for allergic rhinitis, alongside INI-4001, a TLR7/8 agonist in Phase 1 oncology trials, plus pre-clinical vaccine adjuvant work.
Founders & leadership
AJ
alan joslynin
Investors · 1
Competitors · 7
by search overlapInmune Bio55 shared keywordsINmune Bio is a clinical-stage biotechnology company developing immunotherapies, including XPro1595, aimed at treating neurodegenerative and psychiatric diseases through a biomarker-directed approach. The company works on translating inflammatory therapies into clinical treatments for neurologic and other diseases.
Immunome53 shared keywordsImmunome is a clinical-stage oncology company developing targeted cancer therapies, including antibody-drug conjugates (ADCs) and small molecules, to address unmet medical needs in cancers such as lymphoma and bladder cancer. It also acquires targeted oncology assets and advances them through manufacturing and clinical development.
Immuneering52 shared keywordsImmuneering develops Deep Cyclic Inhibitors, a class of oncology medicines designed to pulse dosing faster than cancer's adaptive mechanisms to limit resistance and reduce side effects. The company targets more durable tumor control and improved tolerability for cancer patients.
Immune-Onc Therapeutics50 shared keywordsImmune Onc is a biotechnology company developing medicines to treat patients with hard-to-treat cancers and autoimmune diseases, with expertise in translational medicine and clinical development.
Infinimmune47 shared keywordsInfinimmune discovers and develops antibody therapeutics using proprietary sequencing technology and AI-powered optimization. The company serves pharmaceutical and biotech partners developing treatments across 350+ disease targets.
Immunai42 shared keywordsImmunai develops AMICA, a data platform for decoding the immune system to accelerate drug discovery and development. The company serves pharmaceutical and biotech researchers working on inflammatory and oncological therapies.
Immunomic Therapeutics40 shared keywordsImmunomic Therapeutics develops nucleic acid immunotherapy platforms, particularly self-amplifying RNA and plasmid DNA vaccines, for cancer treatment, allergies, and animal health applications. The company's UNITE® platform leverages lysosomal targeting technology to generate immune responses against CMV, HPV, and other tumor-associated antigens across multiple cancer types and allergic conditions.
Companies competing with Inimmune for the same Google search keywords, organic and paid, via search-intersection analysis.
Non-dilutive funding · 5 SBIR/STTR awards
Federal grants — no equity taken| Agency | Phase | Year | Amount |
|---|---|---|---|
| National Institutes of Health (NIH)National Institutes of Health | Phase II | 2021 | $1.8M |
| National Institutes of Health (NIH)National Institutes of Health | Phase II | 2020 | $2M |
| National Institutes of Health (NIH)National Institutes of Health | Phase II | 2019 | $1M |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2018 | $592.6K |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2018 | $176.8K |
Source: SBIR.gov award data (U.S. Small Business Administration). SBIR/STTR awards are competitive federal R&D grants and contracts — non-dilutive capital alongside any venture rounds above.
In the news
Frequently asked questions
- What does Inimmune do?
- Inimmune is a clinical-stage biotech company that discovers and develops immunotherapies based on innate immune modulation, including Toll-like receptor agonists, to treat inflammatory conditions such as allergy, cancer, and autoimmune disease. Its lead program, INI-2004, is an intranasal TLR4 agonist in Phase 2 trials for allergic rhinitis, alongside INI-4001, a TLR7/8 agonist in Phase 1 oncology trials, plus pre-clinical vaccine adjuvant work.
- Who are Inimmune's investors?
- Inimmune's investors include Two Bear Capital.